R01 CA102577/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2008	1
2009	4
2010	4
2011	4
2012	3
2013	1
2016	1
2018	2
2019	2
2022	0

1

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.

Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD. Duhen T, et al. Nat Commun. 2018 Jul 13;9(1):2724. doi: 10.1038/s41467-018-05072-0. Nat Commun. 2018. PMID: 30006565 Free PMC article.

2

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA. Jensen SM, et al. Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Semin Oncol. 2010. PMID: 21074068 Free PMC article. Review.

3

Science gone translational: the OX40 agonist story.

Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Weinberg AD, et al. Immunol Rev. 2011 Nov;244(1):218-31. doi: 10.1111/j.1600-065X.2011.01069.x. Immunol Rev. 2011. PMID: 22017441 Free PMC article. Review.

4

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

Moran AE, Kovacsovics-Bankowski M, Weinberg AD. Moran AE, et al. Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14. Curr Opin Immunol. 2013. PMID: 23414607 Free PMC article. Review.

5

Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.

Polesso F, Weinberg AD, Moran AE. Polesso F, et al. Cancer Immunol Res. 2019 Feb;7(2):269-281. doi: 10.1158/2326-6066.CIR-18-0222. Epub 2018 Dec 18. Cancer Immunol Res. 2019. PMID: 30563828

6

OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.

Polesso F, Sarker M, Weinberg AD, Murray SE, Moran AE. Polesso F, et al. J Immunol. 2019 Oct 1;203(7):2011-2019. doi: 10.4049/jimmunol.1900696. Epub 2019 Aug 21. J Immunol. 2019. PMID: 31434709 Free article.

7

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, Akporiaye E, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, Fox BA. Petrausch U, et al. Curr Mol Med. 2009 Aug;9(6):673-82. doi: 10.2174/156652409788970670. Curr Mol Med. 2009. PMID: 19689294 Free PMC article. Review.

8

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.

Moran AE, Polesso F, Weinberg AD. Moran AE, et al. J Immunol. 2016 Sep 15;197(6):2509-21. doi: 10.4049/jimmunol.1502659. Epub 2016 Aug 8. J Immunol. 2016. PMID: 27503208 Free PMC article.

9

Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy.

Gough MJ, Killeen N, Weinberg AD. Gough MJ, et al. Immunology. 2012 Aug;136(4):437-47. doi: 10.1111/j.1365-2567.2012.03600.x. Immunology. 2012. PMID: 22578109 Free PMC article.

10

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.

Redmond WL, Triplett T, Floyd K, Weinberg AD. Redmond WL, et al. PLoS One. 2012;7(4):e34467. doi: 10.1371/journal.pone.0034467. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496812 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results